SCHEMBL29079676

SCHEMBL29079676

O=[N+]([O-])c1ccc(N2CCNCC2C(F)(F)F)cc1

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SIRT6 Q8N6T7 2/20 0.52
ADRB1 P08588 1/20 0.52
POLB P06746 1/20 0.42
MAPT P10636 2/20 0.41
KCNJ1 P48048 1/20 0.41
KCNH2 Q12809 1/20 0.41
HTR7 P34969 2/20 0.40
HTR1A P08908 1/20 0.40
ALDH1A1 P00352 1/20 0.39
CRBN Q96SW2 1/20 0.38
HRH3 Q9Y5N1 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12006408 0.79 MAPT (0.47) SIRT6ADRB1POLBMAPTALDH1A1
SCHEMBL23444067 0.79 SIRT6 (0.56) SIRT6ADRB1POLBMAPTKCNJ1
SCHEMBL23524638 0.79 SIRT6 (0.56) SIRT6ADRB1POLBMAPTKCNJ1
SCHEMBL30958500 0.79 SLC6A2 (0.37) HRH3
SCHEMBL878133 0.78 SLC6A2 (0.53) ADRB1ALDH1A1
SCHEMBL6902076 0.77 SIRT6 (0.48) SIRT6ADRB1POLBMAPTKCNJ1
Hydrochloric Acid SCHEMBL28145406 0.77 SLC6A2 (0.51) ADRB1MAPTALDH1A1
SCHEMBL27665380 0.77 SIRT6 (0.54) SIRT6ADRB1POLBMAPTKCNJ1
SCHEMBL6606833 0.76 SIRT6 (0.52) SIRT6ADRB1POLBMAPTKCNJ1
SCHEMBL22471283 0.76 ADRB1 (0.56) SIRT6ADRB1MAPTKCNJ1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116406259-A Dosage form compositions comprising inhibitors of BTK and mutants thereof 广州麓鹏制药有限公司 2023-07-07 CN disclosed
EP-4196124-A1 DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BTK AND MUTANTS THEREOF Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) 2023-06-21 EP disclosed
WO-2022036171-A1 DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BTK AND MUTANTS THEREOF NEWAVE PHARMACEUTICAL INC. (US) 2022-02-17 WO disclosed